Reaction from the field
The emergence of the cicada COVID variant, officially designated BA.3.2, has raised significant concerns across the United States as it spreads rapidly, detected in at least 25 states as of mid-February 2026. This highly mutated variant is known to possess between 70 and 75 mutations in its spike protein, which may allow it to evade the immune response generated by vaccines and prior infections. Public health officials are closely monitoring this situation, given the potential implications for community health.
First identified in South Africa in November 2024, BA.3.2 has since made its way to at least 23 countries. The variant was classified as a ‘variant under monitoring’ by the World Health Organization (WHO) in December 2025, indicating its potential risk to global health. In the U.S., BA.3.2 was first detected in June 2025, and its presence has been confirmed in wastewater samples, with 11% of samples collected during the week ending March 21, 2026, showing traces of the variant.
Common symptoms associated with BA.3.2 include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. While the variant’s mutations may alter its appearance to the immune system, experts like Dr. Andrew Pekosz emphasize the need for continued vigilance, stating, “It has a lot of mutations that may cause it to look different to your immune system.” This highlights the importance of ongoing research to understand the variant’s behavior.
Despite the concerning mutations, some experts have reassured the public. Dr. Adolfo García-Sastre noted that there is currently no evidence suggesting that BA.3.2 is causing more severe disease or increased hospitalizations in regions where it has become widespread. Furthermore, Dr. Amesh A. Adalja has expressed confidence in the existing vaccines, stating, “The existing vaccine is likely to protect against what matters most: serious illness.” This suggests that while vigilance is necessary, the current vaccines may still provide essential protection against severe outcomes.
However, uncertainties remain regarding the full impact of BA.3.2 on disease severity and the effectiveness of current vaccines against this variant. The reasons behind the resurgence of BA.3.2 are not fully understood, leaving public health officials and the community with many questions. Details remain unconfirmed, and ongoing research is crucial to provide clearer answers.
As the cicada COVID variant continues to spread, communities are urged to remain proactive in their health measures, including vaccination and adherence to public health guidelines. The situation is dynamic, and local health departments are working tirelessly to monitor and respond to the evolving landscape of COVID-19 variants.
In the coming weeks, further developments are expected as scientists and health officials gather more data on BA.3.2. The community’s response will play a vital role in managing the spread of this variant and protecting public health. Staying informed and prepared will be key as we navigate these uncertain times together.
